Business

Announcement on Voluntary Disclosure of First Patient Dosed in Phase III Clinical Trial of T-Bren (HER2 ADC) for First-Line Treatment of Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with HER2 Mutations

Announcement on Voluntary Disclosure of First Patient Dosed in Phase III Clinical Trial of T-Bren (HER2 ADC) for First-Line Treatment of Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with HER2 Mutations

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AOctober 20, 20255/news/announcement-on-voluntary-disclosure-of-first-patient-dosed-in-phase-iii-clinical-trial-of-t-bren-her2-adc-for-first-line-treatment-of-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer-with-her2-mutations
Announcement on Voluntary Disclosure of First Patient Dosed in Phase III Clinical Trial of T-Bren (HER2 ADC) for First-Line Treatment of Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with HER2 Mutations

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of First Patient Dosed in Phase III Clinical Trial of T-Bren (HER2 ADC) for First-Line Treatment of Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with HER2 MutationsThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A